Replidyne Seeks Another Partner Before Conducting New Phase III Orapem Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests four additional studies to reconsider a new NDA for antibiotic candidate that was previously deemed “not approvable.”